Evaluation of response to arsenic trioxide in patients with refractory multiple myeloma

Sanaat, Zohreh; Rezazadeh, Mahtab; Gharamaleki, Jalil Vaez; Ziae, Jamal Eivazi; Esfahani, Ali; Ghojazadeh, Morteza
March 2010
Tehran University Medical Journal;Mar2010, Vol. 67 Issue 12, p843
Academic Journal
Background: Multiple myeloma is a plasma cell dyscrasia characterized by proliferation of plasma cells in bone marrow associated with the production of monoclonal immunoglobulins. In recent years, the use of arsenic trioxide, formerly approved for treatment of acute promyelocytic leukemia has been considered for refractory myeloma treatment. This study was designed and carried out to evaluate the efficacy and possible side effects of ATO on patients with refractory multiple myeloma. Methods: This study carried out on myeloma patients whose diseases were at least refractory to two standard treatment regimens conducted in Ghazi Tabatabaei Hospital in Tabriz- Iran. Arsenic trioxide was administered as an intravenous infusion at a dose of 0.25 mg/kg/d for 5 d/week during the first two consecutive weeks of each 4-week cycle with two week rest. Patients who completed one 4-weak cycle were evaluated for response to treatment. Results: Twelve patients with refractory disease to conventional treatment regimens received arsenic trioxide. The response to the treatment assessed based on the amount of serum proteins electrophoresis of the 10 patients. Stable disease observed in four patients (33%), progressive disease in five patients (41.6%), complete response in one (3.8%) and the remaning two patients could not be assessed for response (because of increased liver enzymes after the first week). One patient completed six cycles. Some adverse events such as: increase liver enzymes and serum creatinine, neutropenia, pruritus, nausea, vomiting, lower extremities edema, and noninfectious diarrhea were observed. Conclusions: The use of arsenic trioxide is promising in treatment of refractory multiple myeloma.


Related Articles

  • VELCADE (VEL-kade) (INJECTION).  // Drug Topics;7/07/2003, Vol. 147 Issue 13, p28 

    Provides information on the drug Velcade for the treatment of multiple myeloma or blood plasma cell cancer. Generic name; How to use and store the medicine; Storage and disposal; Drugs and foods to avoid.

  • Elotuzumab: a new monoclonal antibody for multiple myeloma therapy. Staderini, Michela; Nozzoli, Chiara // Drugs & Cell Therapies in Hematology;2016, Issue 1, p68 

    For decades, since its first description, multiple myeloma represented a hard challenge for clinicians due to the scarce results obtained with conventional chemotherapies. Autologous stem cells transplantation and novel drugs such as immunomodulating drugs (IMIDs) and proteasome inhibitors (PIs)...

  • Arsenic Trioxide in Patients with Refractory Multiple Myeloma: A Prospective, Phase II, Single-Arm Study. Sanaat, Zohreh; Rezazadeh, Mahtab; Gharamaleki, Jalial Vaez; Ziae, Jamal Eivazi; Esfahani, Ali // Acta Medica Iranica;2011, Vol. 49 Issue 8, p504 

    Multiple myeloma (MM) characterized by proliferation of plasma cells in bone marrow and production of monoclonal immunoglobulin's. Recently, arsenic trioxide (ATO), has been considered for treatment refractory MM. We assessed the safety and efficacy of ATO for patients with refractory MM. A...

  • Bone marrow immunoscintigraphy using technetium-99m anti-granulocyte antibody in multiple myeloma. Sohn, Sang-Kyun; Ahn, Byeong-Cheol; Lee, Sang-Woo; Kim, Dong-Hwan; Chun, Kyung-Ah; Kim, Jung-Gyun; Park, So-Hyang; Song, Hong-Suk; Lee, Bo; Lee, Jaetae // European Journal of Nuclear Medicine & Molecular Imaging;2002, Vol. 29 Issue 5, p591 

    Conventional skeletal radiography and bone scan have certain limitations in the initial evaluation of bone and bone marrow lesions in multiple myeloma (MM). In this study we investigated the value of bone marrow immunoscintigraphy (BMIS) using anti-granulocyte monoclonal antibody (AGA) for the...

  • Arsenic trioxide/fluconazole/ fluvoxamine interaction.  // Reactions Weekly;12/17/2011, Issue 1382, p9 

    The article describes the case of a man with acute promyelocytic leukaemia (APL) who developed QT interval prolongation during treatment with arsenic trioxide, fluvoxamine and fluconazole and showed selective serotonin reuptake inhibitor (SSRI) discontinuation syndrome after fluvoxamine withdrawal.

  • Treatment of plasma cell dyscrasias with lenalidomide. Dimopoulos, M A; Kastritis, E; Rajkumar, S V // Leukemia (08876924);Jul2008, Vol. 22 Issue 7, p1343 

    Lenalidomide is an immunomodulatory drug, structurally related to thalidomide, with pleiotropic activity including antiangiogenic and antineoplastic properties. It is the product of advances in our understanding of the biology of myeloma cells, their interactions with the microenvironment and of...

  • Arsenic trioxide may improve survival in adults with APL. Harris, Jason; Hasson, Matt; Lawrence, Leah; Southall, Jennifer; Volansky, Rob // Hem/Onc Today;12/10/2010, Vol. 11 Issue 23, p53 

    The article focuses on a study which describes the impact of consolidation treatment with arsenic trioxide on the survival and disease-free survival (DFS) rates of patients with acute promyelocytic leukemia, published in an issue of "Blood."

  • Crystalloid podocytopathy with focal segmental glomerulosclerosis in PCM: a case report. You La Jeon; Woo In Lee; Yujin Choi; So Young Kang; Myeong Hee Kim; Sung-Jig Lim; Sang Ho Lee // Diagnostic Pathology;12/16/2015, Vol. 10 Issue 1, p1 

    Background: Crystalloid podocytopathy with focal segmental glomerulosclerosis in plasma cell myeloma (PCM) is rare. Case Presentation: We present a case of crystalline deposition in the bone marrow (BM) and various renal cells with only proteinuria as a symptom. As workup for proteinuria, a...

  • Arsenic trioxide inhibits the proliferation of myeloma cell line through notch signaling pathway. Jiasheng Hu; Xiao Huang; Xiuli Hong; Quanyi Lu; Xiongpeng Zhu // Cancer Cell International;2013, Vol. 13 Issue 1, p1 

    Arsenic Trioxide (ATO) has shown remarkable efficacy for the treatment of multiple myeloma (MM). However, the mechanism by which ATO exerts its inhibitory effect on the proliferation of myeloma cells remains to be clarified. We study the inhibitory effect of ATO at various concentrations on the...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics